Cheil Bio Co

Cheil Bio Co Net Debt / EBITDA

Delisted·Feb 25, 2026

The Net Debt to EBITDA of Cheil Bio Co (052670.KQ) as of Nov 17, 2026 is 10.32. In the previous year, Net Debt to EBITDA was 15.04 — a change of -31.40% (lower).

Net Debt / EBITDA

10.32

YoY

-31.40%

Last updated:

Net Debt to EBITDA of Cheil Bio Co is 2023 10.32 . Net Debt to EBITDA of Cheil Bio Co was 2022 15.04 . It decreases by -31.40% lower compared to the previous year.

The Cheil Bio Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2016
-20.37 KRW
Jan 1, 2017
-10.29 KRW
Jan 1, 2018
-8.91 KRW
Jan 1, 2019
-27.05 KRW
Jan 1, 2020
71.69 KRW
Jan 1, 2021
16.04 KRW
Jan 1, 2022
15.04 KRW
Jan 1, 2023
10.32 KRW
The Cheil Bio Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
10.32-31.40%
15.04-6.25%
16.04-77.63%
71.69-365.05%
-27.05+203.44%
-8.91-13.34%
-10.29-49.51%
-20.37+48.16%
-13.75-1,903.94%
0.76-170.60%
-1.08-1,675.60%
0.07-102.68%
-2.56-42.73%
-4.47+49.62%
-2.98-625.63%
0.57-46.15%
1.05-93.23%
15.56+313.50%
3.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cheil Bio Co Stock analysis

What does Cheil Bio Co do? Cheil Bio Co., Ltd. generates revenue through the production and sale of veterinary products for pigs, cattle, chickens, cows, and aquatic animals. The company offers antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, and diagnostic kits including ELISA test kits, virus test kits, and DNA kits. These products are primarily sold to the domestic market, targeting livestock farmers and veterinary clinics. The firm also provides feed additives as part of its product portfolio. The company's product range includes specialized solutions for cattle, pigs, chickens, pets, and other animals, with a focus on health management and disease prevention. Veterinary clinics and livestock farms form the core customer segments, purchasing antibiotics, vaccines, and diagnostic tools to maintain animal health. The domestic market remains the primary sales channel, with no mention of international distribution. Cheil Bio's offerings are designed to address common health challenges in livestock, such as infections and parasitic infestations, through both preventive and therapeutic products. The inclusion of diagnostic kits like ELISA and DNA tests supports advanced veterinary care, enhancing the company's value proposition for professional animal health providers. Cheil Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cheil Bio Co stock

Net Debt to EBITDA of Cheil Bio Co is 10.32 in 2023.

Net Debt to EBITDA of Cheil Bio Co changed from 15.04 to 10.32, representing a -31.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Cheil Bio Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Cheil Bio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cheil Bio Co

All Key Metrics — Cheil Bio Co